GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nymox Pharmaceutical NYMXF · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.04

+100.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

—

FY2015FY2024

Net income

−$4.5m

FY2015FY2024

Free cash flow

−$2.6m

FY2015FY2024

Shareholders' equity

−$6.8m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue————$10,000$120,000$300,000$220,000$280,000$2.8m
Gross profit—————$60,000$160,000$80,000$110,000$2.6m
Research and development$3.3m$4.0m$3.8m$6.7m$8.1m$7.4m$6.7m$7.9m$6.8m$8.6m
Operating income−$4.3m−$8.3m−$6.7m−$12.5m−$11.7m−$13.3m−$10.6m−$13.2m−$12.9m−$17.7m
Net income−$4.5m−$8.8m−$6.6m−$12.5m−$11.7m−$13.2m−$10.6m−$13.4m−$13.1m−$17.9m
Diluted earnings per share-0.05-0.10-0.07-0.15-0.16-0.19-0.18-0.26-0.28-0.48

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$654,000$627,000$1.6m$1.4m$4.3m$5.5m$8.1m$980,000$2.1m$710,000
Cash and short-term investments$74,000$70,000$1.4m$830,000$3.6m$5.2m$8.0m$850,000$2.0m$370,000
Total liabilities$7.4m$3.8m$2.1m$1.9m$2.2m$2.0m$1.1m$2.2m$2.3m$3.1m
Debt——$170,000$390,000$430,000$150,000——$930,000$810,000
Shareholders' equity−$6.8m−$3.2m−$480,000−$510,000$2.1m$3.5m$7.0m−$1.3m−$240,000−$2.4m
Shares outstanding94m92m89m82m74m69m60m53m46m37m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$2.6m−$4.1m−$5.2m−$9.8m−$10.0m−$7.4m−$7.8m−$6.2m−$4.5m−$3.8m
Capital spending—−$3,000—−$10,000−$10,000—−$40,000———
Free cash flow−$2.6m−$4.1m−$5.2m−$9.8m−$10.0m−$7.4m−$7.8m−$6.2m−$4.5m−$3.8m

Latest quarters

By quarter end

Dec 2024Sept 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022
Revenue——————−$5,000—
Gross profit——−$3,000−$3,000−$2,000−$3,000−$3,000—
Operating income−$788,000−$653,000−$4.9m−$1.0m−$1.1m−$1.4m$1.7m−$1.5m
Net income−$857,000−$716,000−$5.3m−$1.0m−$1.1m−$1.4m−$1.3m−$1.5m
Diluted earnings per share-0.01-0.01-0.06-0.01-0.01-0.01-0.01-0.02
Cash from operations———−$1.0m——−$1.0m−$1.0m
Total assets$654,000$624,000$627,000$669,000$271,000$575,000$1.6m$3.1m
Cash and short-term investments——$70,000$76,000$132,000$351,000$1.4m—
Debt——$750,000$11,000$805,000$114,000$173,000—
Shareholders' equity−$6.8m−$6.3m−$3.2m−$1.9m−$2.9m−$1.8m−$482,000$773,000

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-30.0%-20.3%-1.0%
Net income-29.0%-19.3%-0.2%

Valuation history

At each fiscal year end

FY2024FY2020FY2019FY2018FY2017FY2016
Price to earnings-0.0—————
Price to sales—0.80.10.00.00.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return6%1454%28%60%-57%15%56%-59%17%60%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.